Research into weight-loss drugs, including Ozempic, suggests they may have a role in controlling weight gain during breast cancer treatment and potentially reducing the risk of breast cancer. Some studies indicate that these drugs, known as GLP-1s, may lower the risk of breast cancer, although the extent of this benefit is not consistently reported. The relationship between weight-loss drugs and breast cancer risk is still being explored, with various organizations and studies contributing to the ongoing research.